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Abstract: Grass pollen is a very common cause of allergic rhinitis and asthma. The only 
treatment targeting the underlying causes of allergy is immunotherapy (IT). Sublingual 
immunotherapy (SLIT) has been introduced to solve the problem of systemic reactions to 
subcutaneous IT (SCIT). This article evaluates the characteristics of the allergen extract, 
Staloral, in terms of practical administration, effectiveness, safety, and mechanism of action. 
Efficacy data were obtained from double-blind, placebo-controlled studies using Staloral in 
patients sensitized to grass pollen, while practical administration, cost-effectiveness, and 
mechanism of action data were provided by well designed studies. The efficacy and safety of 
Staloral, as demonstrated by review of published studies which used doses up to 1125 times 
those administered with SCIT, shows that this allergen extract has optimal characteristics for 
treating patients with seasonal allergies due to grass pollens. The main mechanism of action 
is the interaction between dendritic cells of the oral mucosa and the subsequent tolerance 
induced in T-cells.
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Introduction
Grass pollen is a major source of respiratory allergy throughout the world.1,2 Grasses 
include a high number of species, which have variable importance in different geographical 
areas. In Europe, Dactylis glomerata, Poa pratensis, Lolium perenne, and Anthoxantum 
odoratum are homogeneously distributed, while Phleum pratense is the dominant grass in 
Northern regions and in the UK, and Cynodon dactylon occurs only in Southern regions 
(Table 1). In the US, the species cited above are diffusely spread, while C. dactylon is 
present only in the Northeast, Midwestern, and South/Southeast regions.
Allergy to grass pollen can be treated by symptomatic drugs, namely   antihistamines, 
topical and systemic corticosteroids, and antileukotrienes, but only specific   immunotherapy 
(IT) is able to act on the cause of allergy and to modify the natural history of the disease.3 
IT was introduced in 1910,4 demonstrated to be effective by a controlled trial in 1954,5 and 
established further as effective in meta-analyses of studies of traditional, subcutaneous 
immunotherapy (SCIT),6,7 as well as sublingual immunotherapy (SLIT).8 Most immu-
notherapy studies were performed using extracts containing multiple grasses, but there 
are trials using only D. glomerata, P. pratense, or L. perenne, on the basis that they have 
all the relevant grass allergens. However, thus far, there are no immunologic data dem-
onstrating that extracts of single grasses are equivalent to multiple grass extracts in terms 
of IgE-binding capacity in sera from grass allergic patients. This suggests that   multiple 





Allergen extracts to be used for IT should have all the   relevant 
allergens from the naturally occurring source, in a known and 
reproducible composition. For many years extracts used for SCIT 
were measured in arbitrary units or in protein nitrogen units, but 
in the 1990s SLIT was introduced as a consequence of allergen 
extract standardization, that is, with a known composition, and 
constantly reproducible on a lot-to-lot basis, thereby ensuring 
adequate quality of allergen products.10 Availability of high-
quality, standardized extracts meets the need for indications of 
IT, ie, moderate to severe rhinitis and mild to moderate asthma.3 
This paper describes the development of a standardized grass 
pollen extract (  Staloral, Stallergenes, Antony, France) for the 
treatment of grass pollen-induced rhinitis and asthma.
Standardization of Staloral
The process of standardization is summarized in Figure 1. The 
index of reactivity (IR) is the biologic unit used; a concentra-
tion of 100 IR is determined by the capacity of the allergen to 
elicit by skin prick test a geometric mean wheal size of  7 mm 
diameter in 30 patients sensitized to the corresponding allergen. 
During the standardization procedure, the material is in the 
liquid phase. The product must be stored between 2°C and 8°C. 
At room temperature, the extract is stable for three months.
Several allergen extracts for SLIT are currently marketed 
in Europe, and vary in the amount of allergens contained. 
Almost all of the commercially available SLIT vaccines in 
Europe are standardized biologically or immunologically,11 but 
because the standardization methods are based upon   in-house 
references, the different extracts are labeled in units that differ 
from manufacturer to manufacturer. On the other hand, during 
the last few years, labelling of the content of major allergens 
in µg has been a significant improvement, enabling a rough 
comparison of different therapeutic regimens.
Practical administration
SLIT allergen extract solution can be delivered by drop-
counters, pre-dosed actuators (mini-pumps), or disposable 
single-dose vials. Staloral100 IR was initially administered 
by a drop-counter, but subsequently a   mini-pump pre-dosed 
  actuator was introduced, and is the same as the one used for 
Staloral 300 IR. The allergen extract is usually taken in the 
morning before breakfast, is kept under the tongue for few 
minutes, and then swallowed. The acronym SLIT, unless 
otherwise stated, indicates the sublingual-swallow modality.
Administration regimens
SLIT traditionally involves an uptitration phase followed 
by maintenance treatment with the maximal dose.8 In the 
past the uptitration phase has lasted 4–6 weeks, but this has 
progressively been shortened. The extract is available in vials 
at concentrations of 10, 100, and 300 IR. Other concentra-
tions are available for sensitized patients. The patient must 
start with the lowest concentration and gradually increase, 
according to the physician’s prescription, until the mainte-
nance dose is reached. Rush and ultra-rush inductions have 
also been proposed for routine use, based on the favorable 
safety profile of Staloral, including in children under the 
age of five years.12 Ultra-rush schemes with a build-up shorter 
than two hours have been reported in adults13 and children,14 
with satisfactory results.
The maintenance dose is generally the same for all 
patients, based on clinical results. The maintenance dose 
recommended for Staloral is eight pressures corresponding to 
16.8 µg of the major allergen Phl p 5 for six months/year.
The use of the same dose for all patients is justified on 
the basis that, in contrast with SCIT, the administration of 
very high amounts of allergens does not provoke severe side 
effects. The maintenance dose could be administered at vari-
able time intervals but the once-daily simplifies the regimen 
by assuming the dose as done with almost all drugs.
Criteria for starting and stopping 
treatment
Staloral can be administered either pre-coseasonally (  starting 
2–4 months before and stopping at the end of the pollen   season), 
coseasonally (only during the pollen season), or   continuously.15 
In the pre-co-seasonal and co-seasonal regimen, no dose 
reduction during the pollen season is usually necessary, since 
Table 1 Distribution of grass species in europe
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there is no decrease in safety.16 A recent study reported that a 
coseasonal schedule of 300 IR/day for three years had a carry-
over effect following Staloral discontinuation.17
Clinical efficacy
The first studies on SLIT used very low or low doses,18 but it 
subsequently became apparent that 50- to 100-fold higher doses 
than those administered for SCIT were needed to ensure clinical 
efficacy,19 thereby introducing the concept of “high-dose SLIT”. 
Staloral can be classified in this category because the ratio with 
the extract used for SCIT is higher than 50 (in most studies 
higher than 300) for any allergen used. Thus far, the results 
of eight studies of SLIT with grass pollen are available, all 
demonstrating significantly lower mean symptom/  medication 
Collection and selection of raw pollens
Sieving, drying, storage,
Supplier checking, receiving checking
Macroscopic and microscopic identification
of components from raw materials
Comparison of the protein profile with the in-
house reference by Iso electric focusing (IEF)
of sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE);
Dosage of the allergen activity in 
comparision with the in-house reference
by ELISA inhibition
Dosage of major allergens
Extraction in optimized conditions in Good
Manufacture Processing for each extract
Clarifying filtration with elimination of extractive
salts and low molecular weight substances
Adjustment of dosage of the allergen activity in
comparison with the in-house reference
Standardization in Index of Reactivity (IR)





scores in adult patients20–24 and children17,21,25,26 treated with 
Staloral compared with placebo-treated controls.
Table 2 reports the main data from the published studies 
evaluating Staloral for grass pollen allergy. In one additional, 
randomized, open-label study, different doses of Staloral were 
compared, demonstrating that the 300 IR maintenance dose had 
optimal effectiveness in terms of immunologic response.27
Cost-effectiveness
Currently, cost-effectiveness is an important issue in 
health care. Some studies have addressed this question in 
SLIT treatment with Staloral. The first published study evalu-
ated the cost-effectiveness of SLIT in 135 children with aller-
gic rhinitis and asthma (89 of whom were sensitized to grass 
pollen) by assessing direct costs (drugs, specialists visits, 
and SLIT) and indirect costs (costs resulting from absences 
from school and work). A substantial reduction was found 
in all outcome measures after the start of SLIT treatment, 
indicating that high-dose SLIT may be effective in reducing 
the economic burden of allergic rhinitis and asthma.28
A second study was done using a decision tree populated 
with epidemiologic and resource utilization data for approxi-
mately 2200 adults with pollen allergy attending 25 Italian 
centers over a six-year period.29 Assessment criteria for the 
pharmacoeconomic analysis included direct medical costs 
from the National Health Service perspective (ie, visits, diag-
nostic procedures, drugs, SLIT, and hospitalizations), and 
indirect costs (lost working days and patient out-of-pocket 
expenses) from the societal perspective. Endpoints used 
for effectiveness included number of patients improved 
by treatment and number of asthma cases avoided. Finally 
incremental costs per improved patient and incremental costs 
per asthma case avoided were measured. A mean cost per 
patient treated over a period of six years was calculated for 
each therapeutic strategy and for each of the two perspectives 
studied. The SLIT strategy resulted in less expense in term of 
both direct and indirect costs. The break-even point of SLIT, 
ie, the time at which the overall cost of treatment for SLIT 
patients becomes lower than for patients receiving drugs only 
for the societal perspective was reached at four years.
A third pharmacoeconomic study evaluated SLIT in 
patients with pollen allergy and suffering from allergic rhinitis 
alone or in association with asthma compared with standard 
case-controls.30 This study used a longitudinal observational 
database operated by a network of allergy centers. Patients 
were randomly assigned to SLIT (plus drugs as needed) or to 
treatment with drugs alone. The outcome measures included 
use of drugs, SLIT, visits, and tests. Costs were assessed from 
the Italian National Health Service perspective. The results 
showed that the overall per patient yearly cost of treatment 
was higher in SLIT patients than in those who received drugs 
alone, both in the whole sample (€311 versus €180 per 
patient, respectively), and in the rhinitis (€288 versus €116) 
and rhinitis associated with asthma (€362 versus €230) 
subgroups. Patients with both rhinitis and asthma generated 
more costs than those with rhinitis alone in both groups. 
Nevertheless, considerable savings were made in terms of the 
cost of drugs used to treat symptoms (-22% for rhinitis, -34% 
for rhinitis and asthma) in SLIT patients. Previous efficacy 
studies8 have shown that SLIT can reduce the use of drugs 
for symptomatic relief, but this is the earliest research dem-
onstrating this outcome in a patient population seen in routine 
clinical practice during the first year of treatment.
These studies indicate that SLIT may be beneficial to 
the health care system, in that it could bring more clinical 
effectiveness at a reduced cost in comparison with standard 
drug treatment, as well as have the potential to accrue extra 
benefit at an acceptable additional cost.31
Safety and tolerability
SLIT was developed with the specific goal of   improving safety 
and this issue is of particular importance. As   demonstrated in 
Table 2 Published studies of SLiT with Staloral grass pollen
Reference Maintenance Protocol Treatment duration Major allergen  
mean dose/month 
SLIT/SCIT ratio
20 Daily Pre-coseasonal 4 months 210 Dac g 5 50
21 Daily Pre-coseasonal 6 months 433.3 µg Phl p 5 500
22 Daily Pre-coseasonal 4 months 233.8 µg Phl p 5 150
25 Alternate days Continuous 12 months 210 µg Dac g 5 150
23 Alternate days Pre-coseasonal 2 years 329 µg Dac g 5 450
24 Daily Continuous  9 months 388 µg Phl p 5  1125
17 Daily Coseasonal 3 years 500 µg Phl p 5 1125
26 Daily Pre-coseasonal 2 years 304 µg Phl p 5 450
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the literature, the majority of adverse events involve the site 
of contact with the allergen extract, ie, the mouth and both 
upper and lower digestive systems. Most adverse events can 
be easily managed by dose modification (eg, in the event of 
disturbing gastrointestinal reactions, by spitting out the extract 
after having kept it under the tongue for 2–3 minutes). It 
should be noted that SLIT is not generally used under medi-
cal supervision, whereas reporting of side effects is higher in 
clinical trials and post-marketing surveillance.
Importantly, no fatality has ever been described in asso-
ciation with SLIT. Most local side effects are described as 
mild and self-resolving without dose adjustment or medical 
intervention. SLIT must be discontinued very rarely.   Systemic 
side effects (eg, asthma, rhinitis, urticaria, angioedema) have 
been reported only occasionally in the available   controlled 
studies.
In 2000, André et al examined the safety of SLIT in the 
eight trials performed with Staloral at that time.32 These 
  studies involved 690 subjects (347 on active treatment and 
343 on placebo), including 218 children aged 5–16 years (103 
active and 115 placebo). The majority of adverse events were 
mild and their occurrence did not differ between the active 
and placebo groups. The only differences were for oral and 
gastrointestinal side effects that were more frequent in SLIT 
patients, although mild. Adverse event and dropout rates were 
similar in adults and children.
In 2005 a systematic review of the relevant published   studies 
evaluated dose-related adverse event rates, expressed as the ratio 
between SLIT and the equivalent SCIT.33 In total, 25 studies 
were analyzed, of which 13 studies had used low doses (doses 
ranging from one to 50 times the dose commonly administered 
with SCIT), and 12 had used high doses (doses ranging from 
50 to 500 times the dose administered with SCIT). Local reac-
tions were significantly more frequent in the low-dose group 
than in the high-dose group (P , 0.0001), but there was no 
difference in systemic reaction rates between low- and high-
dose groups. No severe systemic reactions were reported. This 
review provided evidence that the occurrence of side effects 
during SLIT, unlike with SCIT, is not dose-dependent.
Very recently, two cases of anaphylaxis to an   alternative 
grass pollen tablet were reported,34 along with two 
  respiratory reactions to the grass pollen tablet manufactured 
Stallergenes,35 all occurring in patients who had experienced 
previous systemic reactions to SCIT. These reports suggest 
that poor tolerance of SCIT may need to be considered as a 
potential contraindication to use of SLIT.36
The question of use of high-dose SLIT in children 
younger than five years (which is the age cut-off for SCIT) 
has also been addressed. An observational safety study has 
been done in 65 children treated with SLIT using an uptitra-
tion phase of 11 days and culminating in a maximal main-
tenance dose of 300 IR three times a week.12 Grass pollen 
was the second most frequently used allergen (after house 
dust mites). Adverse event rates and changes in the treat-
ment schedule were compared in children younger or older 
than five years. The average cumulative dose of SLIT was 
36,900 IR. Adverse reactions were observed in 11 children, 
none of which were severe enough to require discontinuation 
of immunotherapy. Six adverse reactions occurred in children 
younger than five years and seven in the older children. This 
difference was not considered significant.
Mechanism of action
The prophylactic and therapeutic effects of immunotherapy 
are related to its mechanism of action.37 In particular, 
  immunotherapy reduces allergic inflammation even after 
its discontinuation, and so modifies the natural history 
of the allergy. Such anti-inflammatory effects, exerted 
also by SLIT, are based on the ability of immunotherapy 
to modify the   phenotype of T-cells, which in allergic 
  subjects is   characterized by a prevalence of the Th2 type, 
with   production of IL (interleukin)-4, IL-5, IL-13, IL-17, 
and IL-32   cytokines.37 The induced changes result in a 
Th1-type response (immune deviation) related to increased 
IFN-gamma and IL-2 production or to reduced Th2 activ-
ity, through a mechanism of anergy or tolerance. It is now 
known that T-cell tolerance is characterized by the   generation 
of   allergen-specific regulatory T-cells (Treg cells), which 
  produce cytokines, such as IL-10 and transforming growth 
factor-beta, with immunosuppressant and/or immunoregu-
latory activity.38 Recent studies suggest that the antinflam-
matory mechanism of SLIT is similar to that of classical, 
subcutaneous IT,39 with mucosal dendritic cells having a 
prominent role in SLIT. Of note, it has been found in in vitro 
experiments that internalization of allergens by Langerhans-
like dendritic cells is dose-dependent.40 The tolerance pattern 
promoted by dendritic cells and driven by Treg should account 
for the suppressed or reduced activity of inflammatory cells 
and for the isotypic switch of antibody synthesis from IgE 
to IgG, and especially to IgG4. The dose-dependence of the 
immunologic response has also been demonstrated in clini-
cal studies of patients treated with Staloral 300.27 Moreover, 
data obtained from biopsies indicate that the oral mucosa 
plays a pivotal role in inducing tolerance to the sublingually 
administered allergen. In fact, in subjects treated with high-





showed very low numbers of mast cells and eosinophils (ie, 
the effector cells of allergic reactivity) both in the epithelium 
and subepithelium layers, and insignificant changes were 
detected after SLIT.41
Conclusion
SLIT is a safe and effective therapeutic alternative to SCIT 
for allergen immunotherapy (Table 3). Staloral is an effective 
treatment for rhinitis and asthma attributable to sensitization 
to grass pollen. It is now generally accepted that allergen 
doses much higher than those administered by SCIT must 
be used to control allergic symptoms. Such doses can be 
administered in view of the reassuring data on tolerability and 
safety of high-dose SLIT. The efficacy and safety of Staloral, 
as demonstrated by eight double-blind, placebo-controlled 
studies using doses up to 1125 times higher than those 
administered with SCIT,17,20–26 suggests that this allergen 
extract is an attractive therapeutic option for patients with 
seasonal allergies due to grass pollen.
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